In conclusion, PTP-1B expression, as determined by immunohistochemistry, was higher in patients with adverse pathological factors in prostatectomy specimens, independently of T2DM or prior metformin use. This evidence concerns the gene PTPN1 and type 2 diabetes mellitus.